Medicap Healthcare Ltd. has filed its draft red herring prospectus (DRHP) with SEBI for a ₹240 crore IPO comprised entirely of a fresh issue, with no offer‑for‑sale component. The draft outlines use of proceeds, potential pre‑IPO placement, and listing plans on BSE and NSE.
Offer structure and size
- Issue size: ₹240 crore, 100% fresh issue; no OFS, per the DRHP filing summaries.
- Pre‑IPO placement: Up to ₹48 crore may be raised before the IPO; if exercised, the fresh issue size will be reduced accordingly.
- Listing venues: Proposed listing on NSE and BSE with Aryaman Financial Services as BRLM and KFin Technologies as registrar.
Use of proceeds
- Capex: Purchase of plant and machinery for the existing manufacturing unit.
- Debt reduction: Repayment or prepayment, in full or part, of certain borrowings of Medicap and its subsidiary KASR Healthcare.
- General corporate purposes and investment into subsidiary for deleveraging and growth.
Business overview
Vadodara‑based Medicap Healthcare manufactures critical pharma packaging products, including Euro head caps and PET bottle preforms, serving domestic and export markets; FY25 revenue was reported around ₹108.3 crore with profit of ₹32.78 crore as per media summaries of the DRHP.
Where to find the DRHP
A copy of the filed draft is hosted on exchange/SEBI portals; investors should review risk factors, detailed financials, customer concentration, capex roadmap, and litigation before forming a view.
Next steps and timeline
- SEBI review: Post‑filing, SEBI typically issues observations within a few weeks to months; final timelines depend on regulatory feedback and market conditions.
- RHP & price band: After SEBI observations, the company will file the RHP with final issue details, price band, and schedule.
Bottom line: Medicap Healthcare’s ₹240 crore, all‑fresh issue aims to fund capex and deleveraging while supporting growth in pharma packaging; the DRHP is filed, and the process now moves to SEBI review before pricing and launch.